David Sali

Dave is OBJ’s senior writer and editor with two decades of experience in the newspaper industry working for a variety of publications from community weeklies to major dailies. He is a four-time award-winning journalist by the Alliance of Area Business Publishers (AABP). He has received awards for best news feature, best scoop and best overall writer among medium-sized business publications.

Clearly different: Vars startup’s see-through masks catch RCMP’s eye

Techopia

Country’s largest police force testing InnovaTools’ clear plastic PPE as part of federal R&D program.

Ottawa digital marketing agency eyes software push as revenues soar during pandemic

Techopia

Three-year-old startup says new SaaS-based tool will help ‘level the playing field’ for SMEs competing against corporate giants for ad space on social media.

Ottawa startup sees ocean of opportunities in new carbon-capture technology

Techopia

Planetary Hydrogen’s system that scrubs carbon dioxide from the atmosphere and creates hydrogen – a potential “fuel of the future” – as a byproduct is

Ottawa entrepreneur’s info-sharing app gaining traction in COVID era

Techopia

Maker of mobile application that securely stores health information, schedules and other vital family data lands deals with the Canadian Forces and a local home-care

Ottawa cybersecurity company Titus cuts 20% of staff following acquisition by U.S. firm

Techopia

Ottawa firm that makes software that allows users to classify emails and attachments according to their level of security had about 130 employees before this

Ottawa software maker Amika Mobile acquired by California firm

Techopia

Emergency communications software company hopes deal will help it tap into growing U.S. market.

Calian Group stretches profit streak in Q3, raises 2020 revenue guidance

Techopia

Kanata firm continued to rewrite its corporate record book, posting year-over-year sales gains in three of its four main service lines en route to hitting

Ottawa biotech lab gets $56M shot in the arm for COVID vaccine research

Techopia

Variation Biotechnologies is working with the National Research Council to create a vaccine that would target the novel coronavirus as well as other deadly viruses.